Our journey

2024

Acute Kidney Injury

Kidney failure is characterized by one or both kidneys losing their renal function, namely, the ability to filter waste matter from the blood.

2023

Glial Fibrillary Acidic Protein (GFAP)

GFAP is a biomarker for Traumatic Brain Injury (TBI). It can reach high concentrations in TBI, resulting in physical, cognitive, social, emotional, and behavioral symptoms. Outcomes can range from complete recovery to permanent disability or death.

2022

First Distributed Testing Event

In SensUs 2020 and 2021, both offline SensUs Events were held online due to the coronavirus pandemic. The teams really enjoyed participating in this manner at their own universities. Now that the event can continue offline, the SensUs Organization has launched a new initiative called the Distributed Testing Event. This event allows the teams to prepare for the Eindhoven Testing Event under real competition conditions.

2022

Interleukin-6

Interleukin-6 is a biomarker for acute inflammation and it can reach high concentrations in case of sepsis, a life-threatening condition triggered by infection. Therefore, IL-6 is an important marker for early diagnosis and monitoring of sepsis.

2021

Hemagglutinin

The theme of SensUs 2021 was acute respiratory viruses. The Covid-19 pandemic made it apparent that large virus outbreaks can cause immense harm to human health and can disrupt society as a whole. One of the most common respiratory viruses is influenza A. Biosensors for the detection of influenza A could help to prevent the spread of this virus.

2020

Valproate

Valproate (VPA) is a drug used in the treatment of epilepsy, bipolar disorder and spinal muscular atrophy. Epilepsy affects around 50 million people worldwide. A biosensor for the measurement of VPA could help to the quality of life by personalizing VPA treatment.

2020

First Online SensUs Innovation Days

Unfortunately, due to the coronavirus pandemic, the SensUs Innovation Days could not be organized physically in Eindhoven. However, the show must go on! That is why the SensUs Organization arranged the Innovation Days to be held in a virtual environment.

2019

Adalimumab

SensUs 2019 challenged student teams to develop innovative biosensing systems for the measurement of adalimumab, a biological drug that is prescribed to patients suffering from rheumatoid arthritis (RA). RA affects around 1% of the world population. Measurement of adalimumab concentrations will enable more efficient and effective management of the disease.

2018

Vancomycin

SensUs 2018 challenged student teams to develop innovative biosensing systems for the measurement of the antibiotic drug vancomycin. Antibiotic drugs are widely used in society. Unfortunately, the massive use of drugs causes Anti-Microbial Resistance (AMR). On a personal level, a vancomycin biosensor could help to provide patients with the right dose, thereby increasing the effectiveness and reducing the side effects of drug treatment.

2017

NT-probNP

Heart failure (HF) is a very important public health problem in both developed and developing countries with a prevalence of about 1% of the population. In 2017 SensUs featured NT-proBNP as its target molecule, which is a key biomarker for heart failure.

2016

Creatinine

SensUs 2016 was all about biosensors for kidney failure detection. Creatinine is a waste molecule that is filtered out of the blood by the kidneys. By detecting this molecule, patients can take control of their health by monitoring their kidneys fast and easy.

Our
journey